USPTO serial 97939663
PLV
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- WHELAN, JAIME M
- Law office
- TMO LAW OFFICE 129
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PLV?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Edmonton, Alberta, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Theodore R. Remaklus
Theodore R. Remaklus Thompson Hine LLP312 Walnut Street, Suite 2000Cincinnati, OH 45202-4024United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use | ACTIVE | — |
| 005 | Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the nature of pneumonia, kidneys in the nature of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery system, comprising FAST proteins for intracellular delivery of therapeutic agents; drug delivery system, comprising naturally occurring, engineered and FAST proteins fused to antibodies, polypeptide sequences and targeting ligands, namely, Alpha-V/Beta3, RGD, EGFL7, PC3, Hepsin, Protease cleaved collagen IV and Plectin, for intracellular delivery of therapeutic agents; drug delivery system, comprising charged, ionizable and cationic lipids to neutralize nucleic acid cargo(es) and overall particle charge for intracellular delivery of therapeutic agents; drug delivery system, comprising helper lipids to mediate particle morphology, structure, fluidity and FAST protein stabilization for intracellular delivery of therapeutic agents; drug delivery system, comprising conjugated lipids, namely, pegylated lipids for stability and size, and cargoes, namely, DNA, plasmid DNA, circular DNA, single stranded DNA, RNA, mRNA, siRNA, miRNA, shRNA, tRNA, protein, peptides, small molecules, and combinations thereof for intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies | ACTIVE | — |
| 042 | Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates | ACTIVE | — |
| 044 | Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Entos Pharmaceuticals Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PLV
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 4, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| May 22, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Sep 9, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Sep 1, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Feb 28, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 28, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 28, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 30, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 30, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 30, 2025 | ALIE | ASSIGNED TO LIE | — |
| Jan 28, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 17, 2024 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 17, 2024 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 17, 2024 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 17, 2024 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 17, 2024 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 17, 2024 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Oct 17, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Oct 7, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 7, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 7, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 7, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 7, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 17, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 17, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 17, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 26, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 25, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 25, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 27, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Sep 27, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jun 27, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 27, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 27, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 26, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 15, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 19, 2023 | NWAP | NEW APPLICATION ENTERED | — |